BioGend Therapeutics Co., Ltd.

TPEX:6733 Stock Report

Market Cap: NT$3.4b

BioGend Therapeutics Valuation

Is 6733 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6733 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6733's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6733's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6733?

Key metric: As 6733 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6733. This is calculated by dividing 6733's market cap by their current revenue.
What is 6733's PS Ratio?
PS Ratio20x
SalesNT$167.65m
Market CapNT$3.35b

Price to Sales Ratio vs Peers

How does 6733's PS Ratio compare to its peers?

The above table shows the PS ratio for 6733 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average20.8x
6875 Pharmosa Biopharm
35.8xn/aNT$6.0b
4169 TCM Biotech International
3.7xn/aNT$3.1b
1783 Maxigen Biotech
5.6xn/aNT$3.8b
7808 BIONET Therapeutics
38xn/aNT$3.1b
6733 BioGend Therapeutics
20xn/aNT$3.4b

Price-To-Sales vs Peers: 6733 is good value based on its Price-To-Sales Ratio (20x) compared to the peer average (20.8x).

Price to Sales Ratio vs Industry

How does 6733's PS Ratio compare vs other companies in the TW Biotechs Industry?

13 CompaniesPrice / SalesEstimated GrowthMarket Cap
3176 Medigen Biotechnology
3xn/aUS$125.40m
4169 TCM Biotech International
3.7xn/aUS$95.64m
6562 UBI Pharma
2.6xn/aUS$51.89m
3164 GenMont Biotech Incorporation
4.3xn/aUS$50.59m
6733 20.0xIndustry Avg. 20.0xNo. of Companies13PS020406080100+
13 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6733 is expensive based on its Price-To-Sales Ratio (20x) compared to the TW Biotechs industry average (19.7x).

Price to Sales Ratio vs Fair Ratio

What is 6733's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6733 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio20x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6733's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

AnalystConsensusTarget
Consensus Narrative from 1 Analyst
NT$39.00
Fair Value
30.8% undervalued intrinsic discount
1
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/18 11:51
End of Day Share Price 2025/04/18 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioGend Therapeutics Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xiaowei HuangMasterlink Securities Corp.